PARP1 and breast carcinoma: PARP inhibitor monotherapy shows promising efficacy in breast cancer, with early-stage trials demonstrating progression-free survival (PFS) of 7, 28.7, and 22.1 months for olaparib, rucaparib, and niraparib, respectively.